Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
US Army
Julphar
Accenture
Teva
UBS
QuintilesIMS
Mallinckrodt
Fish and Richardson

Generated: May 23, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,238,924

« Back to Dashboard

Summary for Patent: 5,238,924
Title: Treatment of renal diseases with ace inhibitors
Abstract:There is disclosed the use of angiotensin converting enzyme (ACE) inhibitors to alter the progression of renal diseases by affecting intraglomerular hemodynamics and proteinuria; i.e., affecting blood pressure within the functioning, filtering tissue of the kidney and the quantity of albumin in the urine.
Inventor(s): Smith; Ronald D. (Worchester, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ) Brigham & Women's Hospital (Boston, MA)
Application Number:07/721,790
Patent Claims: 1. A method of treating progressive renal failure which is manifested by such deficiences as intraglomerular hypertension, progressive glomerular sclerosis, progressive proteinuria, azotemia, regardless of the etiology of the initial renal insult which method comprises administering to a patient in need of such treatment a renal failure inhibiting amount of an angiotensin converting enzyme inhibitor carboxyalkyl dipeptide compound.

2. The method of claim 1 wherein said angiotensin converting enzyme inhibitor compound is a member selected from the group consisting of carboxyalkyl dipeptide derivatives;

1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline;

2-[N-(S)-1-ethoxy-carbonyl-3-phenylpropyl)-S-alanyl]-cis,endo-2-aza-bicyclo [3,3,0]octane-3(S)-carboxylic acid;

N-((S)-1-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-N-(2-indanyl)-glycine;

1-(N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-cis,syn-octahydro-(H-in dole-2-S)-carboxylic acid;

2-(N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl)-1,2,3,4-tetrahydroiso- isoquinoline-3(S)-carboxylic acid; and,

1-carboxymethyl-3(S)-(1(S)-ethoxycarbonyl-3-phenylpropylamino)-2,3,4,5-tetr ahydro-1H[1]-benzazepine-2-one.

3. The method of claim 2 wherein said carboxyalkyl dipeptide derivatives are selected from the group consisting of:

N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline;

N-[1(S)-carboxy-3-phenylpropyl]-L-alanyl-L-proline; or,

N-.alpha.-[1(S)-carboxy-3-phenylpropyl]-L-lysyl-L-proline.

4. A method of treating progressive renal failure which is manifested by such deficiencies as intraglomerular hypertension, progressive glomerular sclerosis, progressive proteinuria, azotemia, regardless of the etiology of the initial renal insult which method comprises administering to a person in need of such treatment a renal failure inhibiting amount of an angiotensin converting enzyme inhibitor compound which is a member selected from the group consisting of:

N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline;

N-[1(S)-carboxy-3-phenylpropyl]-L-alanyl-L-proline; or,

N.alpha.-[1(S)-carboxy-3-phenylpropyl]-L-lysyl-L-proline.

5. A method of treating progressive renal failure that comprises administering to a patient in need of such treatment a renal failure inhibiting amount of an angiotensin converting enzyme inhibitor compound.

6. The method of claim 5 wherein said angiotensin converting enzyme inhibitor compound is a member selected from the group consisting of carboxyalkyl dipeptide derivatives;

1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline;

2-[N-(S)-1-ethoxy-carbonyl-3-phenylpropyl)-S-alanyl]-cis,endo-2-aza-bicyclo [3,3,0]octane-3(S)-carboxylic acid; N-((S)-1-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-N-(2-indanyl)-glycine;

1-(N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-cis,syn-octahydro-(H-in dole-2-S)-carboxylic acid;

2-(N-[(S)-1-ethoxy- carbonyl-3-phenylpropyl]-L-alanyl)1,2,3,4-tetrahydroiso-isoquinoline-3(S)- carboxylic acid; and,

1-carboxymethyl-3(S)- (1(S)-ethoxycarbonyl-3-phenylpropylamino)-2,3,4,5-tetrahydro-1H [1]-benzazepine-2-one.

7. The method of claim 6 wherein said carboxyalkyl dipeptide derivatives are selected from the group consisting of:

N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline;

N-[1(S)-carboxy-3-phenylpropyl]-L-alanyl-L-proline; or,

N-.alpha.-[1(S)-carboxy-3-phenylpropyl]-L-lysyl-L-proline.

8. A method of treating progressive renal failure that comprises administering to a person in need of such treatment a renal failure inhibiting amount of an angiotensin converting enzyme inhibitor compound which is a member selected from the group consisting of:

N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proline;

N-[1(S)-carboxy-3-phenylpropyl]-L-alanyl-L-proline; or,

N-.alpha.-[1(S)-carboxy-3-phenylpropyl]-L-lysyl-L-proline.

9. The method of claim 1 wherein the progressive renal failure is caused by glomerulonephritis.

10. The method of claim 1 wherein the progressive renal failure is caused by diabetic nephropathy.

11. The method of claim 1 wherein the progressive renal failure is caused by normotensive diabetes.

12. The method of claim 4 wherein the progressive renal failure is caused by glomerulonephritis.

13. The method of claim 4 wherein the progressive renal failure is caused by diabetic nephropathy.

14. The method of claim 4 wherein the progressive renal failure is caused by normotensive diabetes.

15. The method of claim 5 wherein the progressive renal failure is caused by glomerulonephritis.

16. The method of claim 5 wherein the progressive renal failure is caused by diabetic nephropathy.

17. The method of claim 5 wherein the progressive renal failure is caused by normotensive diabetes.

18. The method of claim 8 wherein the progressive renal failure is caused by glomerulonephritis.

19. The method of claim 8 wherein the progressive renal failure is caused by diabetic nephropathy.

20. The method of claim 8 wherein the progressive renal failure is caused by normotensive diabetes.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Accenture
Deloitte
Covington
Citi
Express Scripts
Argus Health
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.